About ATDBio
ATDBio is a company based in Southampton (United Kingdom) founded in 2005 by Tom Brown was acquired by Biotage in October 2021. The company has 23 employees as of January 31, 2020. ATDBio offers products and services including Oligonucleotide Synthesis, Oligo Calculator, and Nucleic Acids Book. ATDBio operates in a competitive market with competitors including Omniome, HitGen, Novogene Corporation, NuProbe and NovellusDx, among others.
- Headquarter Southampton, United Kingdom
- Employees 23 as on 31 Jan, 2020
- Founders Tom Brown
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Atdbio Limited
- Date of Incorporation 03 Dec, 2004
- Jurisdiction YSTRAD MYNACH, HENGOED, WALES
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of ATDBio
ATDBio offers a comprehensive portfolio of products and services, including Oligonucleotide Synthesis, Oligo Calculator, and Nucleic Acids Book.
Custom design and synthesis of oligonucleotides for research and diagnostics
Online tool for calculating oligonucleotide properties and applications
Free online resource on nucleic acid chemistry and biology
Funding Insights of ATDBio
Investors in ATDBio
ATDBio has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include Biotage, European Union and Innovate UK.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Locked | Locked | Locked | |
|
Organic synthesis, analytical, and peptide chemistry services for drug discovery and development
|
Locked | Locked | Locked |
Investor details for ATDBio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by ATDBio
Investment portfolio details for ATDBio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - ATDBio
Detailed financials for ATDBio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Atdbio Comparisons
Peer comparison for ATDBio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of ATDBio
ATDBio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Omniome, HitGen, Novogene Corporation, NuProbe and NovellusDx, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Genome sequencing platform is provided for clinical diagnostics.
|
|
| Locked | Locked | Locked |
DNA-encoded libraries are developed for drug discovery applications.
|
|
| Locked | Locked | Locked |
Genomic services and solutions with NGS expertise are provided.
|
|
| Locked | Locked | Locked |
Sensitive multiplex platforms for QPCR are developed using toehold probes.
|
|
| Locked | Locked | Locked |
Developer of technology for precision cancer diagnosis and therapies
|
|
| Locked | Locked | Locked |
BGI is engaged in genomics and precision medicine solutions.
|
Detailed competitors of ATDBio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Atdbio
Complete news archive for ATDBio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ATDBio
ATDBio was founded in 2005 and raised its 1st funding round 10 years after it was founded.
ATDBio is headquartered in Southampton, United Kingdom.
As of Jan 31, 2020, the latest employee count at ATDBio is 23.
ATDBio was founded in 2005 and is headquartered in Southampton, United Kingdom. Customised DNA oligonucleotides are developed by the company within the biotechnology sector. Operations focus on producing oligos, fluorescent probes, and long oligos. These products are supplied for applications in research and diagnostic kits. The founder, Tom Brown, leads the efforts in oligonucleotide development.
ATDBio's top competitors include Novogene Corporation, BGI and Singular Genomics.
ATDBio offers Oligonucleotide Synthesis, Oligo Calculator, and Nucleic Acids Book.
ATDBio has 3 investors. Key investors include Biotage, European Union, and Innovate UK.